Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2024 11:00 ET | Source: PharmAla Biotech

PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
April 10, 2024 16:30 ET | Source: PharmAla Biotech

PharmAla Announces Private Placement and Concurrent Debt Settlement

PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
April 05, 2024 08:58 ET | Source: PharmAla Biotech

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
March 18, 2024 08:55 ET | Source: PharmAla Biotech

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
November 09, 2023 08:55 ET | Source: PharmAla Biotech

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
November 07, 2023 08:55 ET | Source: PharmAla Biotech

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments